Manulife (Manufacturers Life Insurance)
RAPT

Manulife (Manufacturers Life Insurance)’s RAPT Therapeutics RAPT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,166
Closed -$50.9K – 3012
2024
Q3 		$50.9K Hold
3,166
– – ﹤0.01% 2986
2024
Q2 		$77.2K Sell
3,166
-1,358
-30% -$62.7K ﹤0.01% 2889
2024
Q1 		$325K Sell
4,524
-1,012
-18% -$141K ﹤0.01% 2353
2023
Q4 		$1.1M Sell
5,536
-2,310
-29% -$286K ﹤0.01% 1748
2023
Q3 		$1.04M Buy
7,846
+5
+0.1% +$816 ﹤0.01% 1708
2023
Q2 		$1.17M Buy
7,841
+177
+2% +$27.6K ﹤0.01% 1578
2023
Q1 		$1.13M Hold
7,664
– – ﹤0.01% 1572
2022
Q4 		$1.18M Sell
7,664
-18
-0.2% -$2.88K ﹤0.01% 1542
2022
Q3 		$1.47M Sell
7,682
-37
-0.5% -$7K ﹤0.01% 1468
2022
Q2 		$1.13M Buy
7,719
+834
+12% +$111K ﹤0.01% 1601
2022
Q1 		$1.2M Buy
6,885
+5,476
+389% +$1.03M ﹤0.01% 1672
2021
Q4 		$414 Buy
1,409
+10
+0.7% +$2.67K ﹤0.01% 2391
2021
Q3 		$347K Buy
1,399
+59
+4% +$15.6K ﹤0.01% 2560
2021
Q2 		$341K Buy
+1,340
New +$250K ﹤0.01% 2718
2020
Q4 		– Sell
-870
Closed -$224K – 3021
2020
Q3 		$224K Buy
+870
New +$193K ﹤0.01% 2492

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s RAPT Position: Q4 2024 in Review

Manulife (Manufacturers Life Insurance) sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 3,166 shares — an estimated $50.9K sold.

Manulife (Manufacturers Life Insurance) first reported a position in RAPT in Q3 2020 and held it in 15 quarters. The position peaked at $1.47M in Q3 2022. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • Manulife (Manufacturers Life Insurance) reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 3,166 RAPT Therapeutics shares in Q4 2024, an estimated $50.9K.
  • Manulife (Manufacturers Life Insurance) first reported a position in RAPT Therapeutics in Q3 2020 and held it in 15 quarters.
  • Manulife (Manufacturers Life Insurance)'s RAPT Therapeutics position peaked at $1.47M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2024, filed 14 Feb 2025.